Science Publishing Group

Children's Hospital of Philadelphia Receives $400,000 Grant from American Heart Association to Study Hormones Related to Cardiovascular Disease and Metabolic Health

Retrieved on: 
Thursday, August 4, 2022
Hospital, Medical laboratory, Hormone, CHOP, Pathology, Research, Degenerative disease, Health, Science Publishing Group, AHA, Twitter, Physiology, Associate, Doctor of Philosophy, American Heart Association, Organization, Philadelphia, Heart, MD, Prussia, Volunteering, Einstein Medical Center Philadelphia, Lists of diseases, Disease, Children's Hospital of Philadelphia, Pharmaceutical industry, Dietary supplement, Facebook

PHILADELPHIA, Aug. 4, 2022 /PRNewswire/ -- Children's Hospital of Philadelphia (CHOP) has received a $400,000 grant from the American Heart Association (AHA) to help study heart-secreted hormones. The funding, which will be disbursed in yearly increments through 2027, supports CHOP researcher Liming Pei, PhD, who studies heart-derived hormones in physiology and disease, an emerging new field known as "cardiac endocrinology."

Key Points: 
  • "Our hearts secrete hormones that play important functional roles in cardiovascular physiology and disease; however, few heart-derived hormones have been identified," said Liming Pei, PhD, Principal Investigator and Associate Professor of Pathology and Laboratory Medicine at the Children's Hospital of Philadelphia.
  • "This grant will provide critical support for a highly innovative research project that could lead to new and better treatments for those with cardiovascular and metabolic diseases."
  • "We, along with the American Heart Association, aspire toadvanceresearchthat improvescardiac care," said Daniel Kelly, MD , Director of the CHOP Cardiovascular Institute.
  • A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital.

Lupus Foundation of America Summer Fellowship Program Awards Grants to Six Young Scientists

Retrieved on: 
Tuesday, August 2, 2022
Division, Education, Awareness, Health informatics, Bioinformatics, Penn State University College of Medicine, Lupus Foundation of America, Research, Doctor of Philosophy, Student, Artificial intelligence, CEO, Gina, Biomarker, Genetics, Associate, Lupus, Risk, Science Publishing Group, Finzi, State University of New York, Public health, Quality of life, MA, State university system, Disease, MD, Interim, Biochemistry, Patient, Genomics, Michigan State University, Professor, Department, Molecular biology, Pathology, Program, Doctor, Growth, Medical laboratory, Pharmaceutical industry, Management, Rheumatology, Immunology, Medicine, Microbiology

WASHINGTON, Aug. 2, 2022 /PRNewswire/ -- The Lupus Foundation of America announces six recipients of the 2022 Gina M. Finzi Memorial Student Summer Fellowship Program , which provides grant and mentorship support to young scientists pursuing the lupus research field.

Key Points: 
  • WASHINGTON, Aug. 2, 2022 /PRNewswire/ -- The Lupus Foundation of America announces six recipients of the 2022 Gina M. Finzi Memorial Student Summer Fellowship Program , which provides grant and mentorship support to young scientists pursuing the lupus research field.
  • "Research grants like the Lupus Foundation of America Gina M. Finzi Student Memorial Fellowship Program are an incredible opportunity to build awareness of lupus and the need for more research of the disease among young scientists," shared Montserrat Anguera, PhD, 2022 Finzi Fellow Mentor.
  • Past recipients from the program have gone on to lead innovative and groundbreaking lupus research and have become distinguished lupus scientists.
  • "The Lupus Foundation of America understands the importance of nurturing young scientists pursuing the field of lupus research, and the Gina M. Finzi Memorial Student Summer Fellowship Program provides not only critical research funding but the mentorship that is crucial to cultivating the lupus researchers of the future," said Stevan W. Gibson, president & CEO, Lupus Foundation of America.

Replay Launches with $55 Million Seed to Reprogram Biology by Writing and Delivering Big DNA

Retrieved on: 
Monday, July 25, 2022
MIT, Genome, MMS, Gene, Retirement, Sangamo Therapeutics, Late, Biological engineering, Pfizer, Company, LinkedIn, Biology, Professor, Brain, Investment, Skin, Eye, OSI, KKR, Doctor of Philosophy, Independent Board for Presbyterian Foreign Missions, Adverum Biotechnologies, Biotechnology, Technology, Library, Life, Growth, AAV, DNA, Insurance, SALT, Industry, Twitter, Neuroscience, CEO, Board, OMX, ONI, Therapy, Synthetic biology, Medicine, Science Publishing Group, CA, Massachusetts Institute of Technology, University, HSV, NYSE, Paul Ruddock, University of California, Berkeley, Stanford School, Senior advisor, Bristol Myers Squibb, Writing, Vaccine, Management, Cryptocurrency, Pharmaceutical industry, Fine chemical, Financial services, Microbiology, Research, Replay, Axial, Ophthalmology, MD

Adrian Woolfson, Executive Chairman, President, and Co-founder of Replay, commented: Genomic medicine has the potential to transform the future of clinical therapeutics.

Key Points: 
  • Adrian Woolfson, Executive Chairman, President, and Co-founder of Replay, commented: Genomic medicine has the potential to transform the future of clinical therapeutics.
  • Our ability to write and deliver big DNA has the potential to disrupt many areas of genomic medicine.
  • Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA.
  • The Company has, additionally, established an enzyme writing product company engaging its evolutionary inference machine learning and genome writing technology to optimize functionality.

Replay Launches with $55 Million Seed to Reprogram Biology by Writing and Delivering Big DNA

Retrieved on: 
Monday, July 25, 2022
MIT, Genome, MMS, Gene, Retirement, Sangamo Therapeutics, Late, Biological engineering, Pfizer, Company, LinkedIn, Biology, Professor, Brain, Investment, Skin, Eye, OSI, KKR, Doctor of Philosophy, Independent Board for Presbyterian Foreign Missions, Adverum Biotechnologies, Biotechnology, Technology, Library, Life, Growth, AAV, DNA, Insurance, SALT, Industry, Twitter, Neuroscience, CEO, Board, OMX, ONI, Therapy, Synthetic biology, Medicine, Science Publishing Group, CA, Massachusetts Institute of Technology, University, HSV, NYSE, Paul Ruddock, University of California, Berkeley, Stanford School, Senior advisor, Bristol Myers Squibb, Writing, Vaccine, Management, Cryptocurrency, Pharmaceutical industry, Fine chemical, Financial services, Microbiology, Research, Replay, Axial, Ophthalmology, MD

Adrian Woolfson, Executive Chairman, President, and Co-founder of Replay, commented: Genomic medicine has the potential to transform the future of clinical therapeutics.

Key Points: 
  • Adrian Woolfson, Executive Chairman, President, and Co-founder of Replay, commented: Genomic medicine has the potential to transform the future of clinical therapeutics.
  • Our ability to write and deliver big DNA has the potential to disrupt many areas of genomic medicine.
  • Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA.
  • The Company has, additionally, established an enzyme writing product company engaging its evolutionary inference machine learning and genome writing technology to optimize functionality.

Epic Bio, Founded by CRISPR Pioneer, Launches to Revolutionize Genetic Medicine With Epigenetic Engineering

Retrieved on: 
Tuesday, July 12, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Engineering, Manufacturing, Clinical Trials, Stanford University, AAV, GEMS, Gene expression, Gene, Biotechnology, Horizons Ventures, University of Maryland School of Medicine, Genetic engineering, Systems biology, University of Oxford, CRISPR interference, Coronavirus Scientific Advisory Board (Turkey), LinkedIn, Neuroscience, Genomics, University of California, Berkeley, CRISPR, Cas, Scientific Advisory Group for Emergencies, Bio, Patient, University of California, San Francisco, University of Washington Department of Bioengineering, Ludwig Cancer Research, Patent, Institute, Science Publishing Group, CRISPR/Cpf1, Human Genome Sciences, A1AD, Doctor of Philosophy, Department, Synthetic biology, Epigenome, Twitter, University, James D. Watson Institute of Genome Sciences, Industry, Maryland School, FSHD, Pharmaceutical industry, Vaccine, Management, Cas9, Biological engineering

Epic was founded by Stanley Qi, Ph.D., a renowned bioengineer and named co-inventor on the CRISPR patent held by the University of California.

Key Points: 
  • Epic was founded by Stanley Qi, Ph.D., a renowned bioengineer and named co-inventor on the CRISPR patent held by the University of California.
  • The company additionally launches with an exclusive license from Stanford University to the ultracompact DNA-binding protein CasMINI for human use.
  • The platform that Epic Bio has built is unparalleled in the field of epigenetic engineering.
  • Epic Bio was founded by Stanley Qi, Ph.D., whose fundamental work in epigenetic engineering includes the invention of CRISPRa (activation) and CRISPRi (interference).

Foundation for a Smoke-Free World Statement on FDA’s Marketing Denial Orders to JUUL Labs, Inc

Retrieved on: 
Thursday, June 23, 2022
Smoke, Public health, Global health, GLOBE, Smoking, ENDS, Smoker, Agricultural diversification, Foundation, Science Publishing Group, Research, Adult, PMI, Health, Tobacco, Pharmaceutical industry

As use and death rates from smoking idle at a precariously high level across the globe, smokers are desperate for more safe options to kick the habit.

Key Points: 
  • As use and death rates from smoking idle at a precariously high level across the globe, smokers are desperate for more safe options to kick the habit.
  • The Foundation for a Smoke-Free World fully appreciatesthe FDAs prior authorization of 23 electronic nicotine delivery system (ENDS) products for adult smokers as appropriate for the protection of the public health.
  • The Foundation for a Smoke-Free World is an independent, U.S. nonprofit 501(c)(3) independent grantmaking organization with the purpose of improving global health by ending smoking in this generation.
  • The Foundation supports its mission through three broad categories of work: Health and Science Research; Agricultural Diversification; and Industry Transformation.

Verismo Therapeutics Announces Research Partnership with the University of Pennsylvania

Retrieved on: 
Tuesday, June 21, 2022
Antibody, Doctor of Philosophy, FDA, University of Pennsylvania, Penn, Technology, View, CEO, CAR, Medical laboratory, Research, Milone, CTL019, MD, Gene editing, University, SRA, IND, Pathology, Patient, Multimedia, Therapy, Science Publishing Group, Pharmaceutical industry, Verismo

PHILADELPHIA, June 21, 2022 /PRNewswire/ -- Verismo Therapeutics, a recent University of Pennsylvania spin-out company behind the novel KIR-CAR platform technology for CAR T-cells, today announces that Penn and Verismo entered into a Sponsored Research Agreement (SRA). Under the SRA, Verismo is funding additional KIR-CAR T-cell focused preclinical research programs at Penn to advance new potential treatment options for solid tumor indications. The research funded under the SRA is expected to be conducted over four years, from 2021 to 2025, in the Penn laboratories of Michael C. Milone, MD, PhD, an associate professor of Pathology and Laboratory Medicine, and Donald L. Siegel, MD, PhD, a professor of Pathology and Laboratory Medicine.

Key Points: 
  • PHILADELPHIA, June 21, 2022 /PRNewswire/ -- Verismo Therapeutics , a recent University of Pennsylvania spin-out company behind the novel KIR-CAR platform technology for CAR T-cells, today announces that Penn and Verismo entered into a Sponsored Research Agreement (SRA).
  • Under the SRA, Verismo is funding additional KIR-CAR T-cell focused preclinical research programs at Penn to advance new potential treatment options for solid tumor indications.
  • Penn'sPerelman School of Medicine receives sponsored research funding from Verismo to support certain research and development programs at Penn.
  • Verismo Therapeutics is a pioneer in dual-chain KIR-CAR T technology, on track to bring its first asset into first-in-human clinical trials in 2023.

Avellino Welcomes Virginia Gambale to its Board of Directors

Retrieved on: 
Wednesday, June 8, 2022
Medical Devices, Health, Genetics, Pharmaceutical, Optical, Biotechnology, Precision medicine, Genome, Biotechnology, Silicon, CRISPR, Committee, Therapy, Multimedia, Machine learning, COVID-19, JetBlue, FD, Lab, Chairperson, Corporate governance, Merrill (company), Newport Music Festival, Bankers Trust, Mathematics, Health, Americans for Technology Leadership, EUA, Audit, Computer science, Partner, Corporation, AI, Deutsche Bank, Vulnerability and Risk Committee, New, National Association, Columbia University, National Association of Corporate Directors, Disease management, General partnership, Board of directors, LLC, Fellows, Marsh McLennan, Growth, Director, CIO, Mentorship, Board, Audit committee, Genomics, Science Publishing Group, NACD, Virtu Financial, Management, Nutanix, Technology

Avellino Lab USA, Inc. (Avellino), a global leader in molecular diagnostics, is pleased to announce the appointment of Virginia Gambale to its Board of Directors.

Key Points: 
  • Avellino Lab USA, Inc. (Avellino), a global leader in molecular diagnostics, is pleased to announce the appointment of Virginia Gambale to its Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20220608005062/en/
    Virginia Gambale, new member of the Board of Directors for Avellino Lab USA.
  • We are thrilled to welcome Virginia to Avellino.
  • A former concert pianist, Ms. Gambale was the Board President of the Newport Music Festival from 2014 to 2019.

On World No Tobacco Day, Foundation for a Smoke-Free World Highlights Efforts to Reduce the Environmental Impact of Tobacco

Retrieved on: 
Monday, May 30, 2022
Smoke, Foundation, Environment, Health, Smoker, Farmer, Hope, Global health, Awareness, WHO, Science Publishing Group, Smoking, Center, Agricultural diversification, Biodiversity, Tobacco industry, ATI, PMI, Tobacco, CAT, Agriculture, Pharmaceutical industry

NEW YORK, May 30, 2022 /PRNewswire/ -- More than one billion individuals still smoke combustible cigarettes, with dire consequences for individual health and our global environment. More needs to be done to address this threat. Agricultural and tobacco harm reduction innovations offer hope and new options to reduce tobacco's carbon footprint, its overall negative impact on the environment, as well as help for smokers to quit combustible cigarettes.

Key Points: 
  • Malawi is one of the largest tobacco-producing countries in the world.
  • The day-to-day work and exposure associated with tobacco farming are harmful to the health of Malawian farmers as well as the surrounding environment.
  • The Foundation for a Smoke-Free World commends the ongoing efforts of the WHO and World No Tobacco Day to raise awareness and push for lasting change.
  • The Foundation supports its mission through three broad categories of work: Health and Science Research; Agricultural Diversification; and Industry Transformation.

On World No Tobacco Day, Foundation for a Smoke-Free World Highlights Efforts to Reduce the Environmental Impact of Tobacco

Retrieved on: 
Monday, May 30, 2022
Smoke, Foundation, Environment, Health, Smoker, Farmer, Hope, Global health, Awareness, WHO, Science Publishing Group, Smoking, Center, Agricultural diversification, Biodiversity, Tobacco industry, ATI, PMI, Tobacco, CAT, Agriculture, Pharmaceutical industry

NEW YORK, May 30, 2022 /PRNewswire/ -- More than one billion individuals still smoke combustible cigarettes, with dire consequences for individual health and our global environment. More needs to be done to address this threat. Agricultural and tobacco harm reduction innovations offer hope and new options to reduce tobacco's carbon footprint, its overall negative impact on the environment, as well as help for smokers to quit combustible cigarettes.

Key Points: 
  • Malawi is one of the largest tobacco-producing countries in the world.
  • The day-to-day work and exposure associated with tobacco farming are harmful to the health of Malawian farmers as well as the surrounding environment.
  • The Foundation for a Smoke-Free World commends the ongoing efforts of the WHO and World No Tobacco Day to raise awareness and push for lasting change.
  • The Foundation supports its mission through three broad categories of work: Health and Science Research; Agricultural Diversification; and Industry Transformation.